Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GPCR
STRONG SELLStructure Therapeutics Inc. · Healthcare · United States · $3.5B · Avg Vol: $37M/d
COMPANY DESCRIPTION
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing oral small molecule therapeutics for chronic diseases, leveraging its proprietary G protein-coupled receptor (GPCR) targeting platform. The company's competitive moat stems from its specialized drug discovery capabilities focused on GPCRs, which are historically challenging yet highly validated drug targets, offering the potential for best-in-class oral therapies in significant disease areas. Structure Therapeutics represents a high-potential biotech firm aiming to address unmet medical needs through innovative pharmacological approaches.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | 38.5M | 41.7K | — |
| EPS | -1.72 | -1.38 | -2.43 | -5.17 | -5.96 | — | -2.55 | -1.43 | -2.08 | — |
| Shares | — | 114.7M | 139.2M | 71.1M | 71.1M | -38.1% | 71.1M | — | — | — |
| Debt | — | 0.3M | 5.5M | 3.9M | 6.5M | 192.2% | 5.8M | — | — | — |
| Equity | — | -115.1M | 453.0M | 864.8M | 1.5B | 83.0% | — | — | — | — |
| Op CF | — | -46.1M | -79.5M | -116.6M | -222.2M | — | -154.7M | — | — | — |
| Inv CF | — | -62.1M | -268.3M | -358.9M | 89.8M | — | — | — | — | — |
| Fin CF | — | 29.0M | 451.5M | 515.3M | 762.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GPCR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GPCR | Structure Therapeutics Inc.(you) | $3.5B | 15 | STRONG SELL |
| CELC | Celcuity Inc. | $4.0B | 14 | STRONG SELL |
| RCUS | Arcus Biosciences, Inc. | $3.6B | 22 | SELL |
| ALMS | Alumis Inc. | $3.6B | 22 | SELL |
| BEAM | Beam Therapeutics Inc. | $2.6B | 17 | STRONG SELL |
| IMNM | Immunome, Inc. | $2.5B | 17 | STRONG SELL |
| MLYS | Mineralys Therapeutics, Inc. | $2.4B | 16 | STRONG SELL |
| VKTX | Viking Therapeutics, Inc. | $4.0B | 21 | SELL |
| SRRK | Scholar Rock Holding Corporation | $5.7B | 15 | STRONG SELL |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.2B | 13 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.6%